Stem Cell Therapy – StemCell Therapy

Vatican hosts conference on advancements in stem cell therapy – Video

♫ Sunday, April 14th, 2013

Vatican hosts conference on advancements in stem cell therapy
http://en.romereports.com.

By: romereports

Read the original here:
Vatican hosts conference on advancements in stem cell therapy - Video

♫ Posted in Stem Cell Therapy | | Comments Off»

StemCells, Inc., Nails Down Controversial, $19 Million Award from California Stem Cell Agency

♫ Sunday, April 14th, 2013

The stock price of StemCells, Inc.,
price today jumped as much as 9 percent after the company disclosed
it had finally concluded an agreement with the California stem cell
agency for a $19.3 million forgivable loan for research twice rejected by the agency's scientific reviewers..

The stem cell agency governing board seven months ago approved the loan to the Newark, Ca., firm. But the
cash was withheld until the financially strapped company could
demonstrate that it could match the size of the loan, as promised in
its application.

The StemCells, Inc., (SCI) application
was nixed two times in 2012 by the agency's scientific reviewers who gave it a
score of 61. In a controversial move, the 29-member board approved the award in early September on a 7-5 vote after former agency
chairman Robert Klein intervened publicly on behalf of the firm. It was the first time that Klein had lobbied the board publicly on behalf of an application. It was also the first time that the board
approved an application that was rejected twice by its reviewers, a
panel of internationally recognized stem cell scientists.

In a press release, Martin McGlynn,
CEO of StemCells, Inc., said,

"With CIRM's support, we are now
able to lay the groundwork that could result in the world's first
neural stem cell trial in Alzheimer's patients."

Both the company and the $3 billion
state research agency were tight-lipped about the nature of the
matching funds from the company, which reported losses of $28.5
million in 2012 on revenues of $1.4 million.

In a brief response to questions from the
California Stem Cell Report, McGlynn said,

“At this time, we
do not intend to elaborate any further on the contents of our press
releases or public filings pertaining to the SVB (Silicon Valley Bank) or CIRM(the stem cell agency) loans.”

Earlier this week, the company reported receiving a $10 million loan from Silicon Valley Bank. Both McGlynn
and the stem cell agency did not answer a question about whether
those funds are being used to back the award from California
taxpayers.

The agency confirmed that the firm was
providing $19.3 million in matching resources. But Kevin McCormack,
senior director of public communications, did not provide any
specifics on the nature of the match. He only said,

“The matching requires
them to demonstrate they have enough funds necessary to
fund SCI’s share going forward as well as their own
operations and other commitments.”

The award was originally for $20
million. We have queried the agency about the smaller figure
announced today.

The company's stock price rose as high as $1.87 earlier today after closing at $1.71 yesterday. It stood at
$1.77 at the time of this writing. Its 52 week high is $2.67, and its
52 week low is $0.59. The loan from Silicon Valley Bank gives the
bank warrants to purchase 293,531 shares of the company at $1.70 over
the next 10 years.

The 10-year loan from CIRM is low risk for the
company, which said its “obligation to repay the loan will be
contingent upon the success” of the research. If a product is
developed, it will take years before it could hit the market.

The award to StemCells, Inc., put
the stem cell agency in a touchy situation involving the company's decision last month to reject an additional $20 million award from
the agency.( It was the first time a recipient has rejected an award.) Neither the company nor the agency would give a reason for
the rejection of the loan for a spinal injury project . However, the
award also required a $20 million match, which undoubtedly tested the company's resources.

The spinal injury application was
scored at 79 by agency reviewers and was routinely approved by the
board. With its withdrawal by the company, the agency, which prides
itself on funding only the best science, was left supporting research
(StemCells, Inc.'s Alzheimer's project) judged significantly inferior
by reviewers with its score of 61.

In response to a question about that
situation, CIRM's McCormack said,

“Our goal is to always fund the best,
most promising science. This is not the first time that our board has
voted to fund a project that the Grants Review Group had not
recommended (this has happened in around 2% of cases) The board did
so for a number of reasons, not the least of which is that this was
the first disease team application that had a goal of moving a
promising stem cell therapy for Alzheimer's towards clinical
trials.”

The round in question, however, had another application dealing with Alzheimer's which was scored at 63,
two points higher than the one from StemCells, Inc. Reviewers also did not recommend funding that application.

The action last September by the
agency board came only after it publicly said the funds would not be
distributed until the StemCells, Inc., could show it could provide
the match, still another first for the agency.

The award triggered a column in
the Los Angeles Times by Pulitzer Prize winning writer Michael
Hiltzik, who said in October that the
process was “redolent of cronyism.” He said a “charmed
relationship” existed among StemCells, Inc., its “powerful
friends” and the stem cell agency.

StemCells, Inc., was founded by
Stanford researcher Irv Weissman, who was a major fundraiser for
Proposition 71, which created the stem cell agency in 2004. Klein
headed the ballot campaign, which spent more than $30 million to win
voter approval. Weissman sits on board of directors of StemCells,
Inc., and holds 124,608 shares in the firm, including 8,630 he reported this month receiving.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/34J6wy7wpLY/stemcells-inc-nails-down-controversial.html

♫ Posted in Stem Cell Therapy | | Comments Off»

Modest Approval from Long-time Stem Cell Agency Critic

♫ Sunday, April 14th, 2013

Of all California's newspapers, The
Sacramento Bee, the only daily paper in the state capital, has long
been the most critical – editorially – of the Golden State's $3
billion stem cell research agency.

Today, however, the newspaper gave a
modest nod of approval to the agency's modest efforts to clean up its
built-in conflicts of interest, which have been cited as a major flaw
by the prestigious Institute of Medicine.

The headline on the Bee's editorial today said,

“Stem cell agency finally addresses
potential for conflicts”

The piece said that Jonathan Thomas,
chairman of the agency, “has taken important steps in
reducing the potential for conflicts within this agency.”

The editorial continued,

“He hasn't
gone as far as we would like, or that independent outside reviewers
have recommended....But he's achieved what's possible, at least for
now, and the board may empower him to go further.”

The Bee referred to action last month
in which the agency's governing board decided, among other things,
that 13 of the 15 board members linked to recipient institutions
could not vote on any grants, although they could participate in
discussion of applications. Twenty-nine persons sit on the board. In
a $700,000 report commissioned by the agency, the Institute of
Medicine recommended a fully independent board.

The Sacramento newspaper said,

“We
think Thomas and the oversight board should go further and adopt the
Institute of Medicine recommendations. But that is politically
unlikely. As is now obvious, it will be up to the Legislature to
fully remove representatives of funding-eligible institutions from
being involved in decisions about grants that could come back to
them.

“Thomas, to his credit, recognizes
that his compromise may not be the perfect solution. He wants to test
out the new policy for a year, and see how it works. There's a lot
riding on the outcome. CIRM is expected to run out of funds in 2017,
and while philanthropy and foundation money could extend that for a
few years, supporters of California stem cell research clearly want
to go back to the ballot to seek additional funding. To make that
case, CIRM supporters can't afford any more scandals about insider
dealing. The next year will reveal whether it is on the right track.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/NowG2d8N5CM/modest-approval-from-long-time-stem.html

♫ Posted in Stem Cell Therapy | | Comments Off»

StemCells, Inc., Nails Down Controversial, $19 Million Award from California Stem Cell Agency

♫ Sunday, April 14th, 2013

The stock price of StemCells, Inc.,
price today jumped as much as 9 percent after the company disclosed
it had finally concluded an agreement with the California stem cell
agency for a $19.3 million forgivable loan for research twice rejected by the agency's scientific reviewers..

The stem cell agency governing board seven months ago approved the loan to the Newark, Ca., firm. But the
cash was withheld until the financially strapped company could
demonstrate that it could match the size of the loan, as promised in
its application.

The StemCells, Inc., (SCI) application
was nixed two times in 2012 by the agency's scientific reviewers who gave it a
score of 61. In a controversial move, the 29-member board approved the award in early September on a 7-5 vote after former agency
chairman Robert Klein intervened publicly on behalf of the firm. It was the first time that Klein had lobbied the board publicly on behalf of an application. It was also the first time that the board
approved an application that was rejected twice by its reviewers, a
panel of internationally recognized stem cell scientists.

In a press release, Martin McGlynn,
CEO of StemCells, Inc., said,

"With CIRM's support, we are now
able to lay the groundwork that could result in the world's first
neural stem cell trial in Alzheimer's patients."

Both the company and the $3 billion
state research agency were tight-lipped about the nature of the
matching funds from the company, which reported losses of $28.5
million in 2012 on revenues of $1.4 million.

In a brief response to questions from the
California Stem Cell Report, McGlynn said,

“At this time, we
do not intend to elaborate any further on the contents of our press
releases or public filings pertaining to the SVB (Silicon Valley Bank) or CIRM(the stem cell agency) loans.”

Earlier this week, the company reported receiving a $10 million loan from Silicon Valley Bank. Both McGlynn
and the stem cell agency did not answer a question about whether
those funds are being used to back the award from California
taxpayers.

The agency confirmed that the firm was
providing $19.3 million in matching resources. But Kevin McCormack,
senior director of public communications, did not provide any
specifics on the nature of the match. He only said,

“The matching requires
them to demonstrate they have enough funds necessary to
fund SCI’s share going forward as well as their own
operations and other commitments.”

The award was originally for $20
million. We have queried the agency about the smaller figure
announced today.

The company's stock price rose as high as $1.87 earlier today after closing at $1.71 yesterday. It stood at
$1.77 at the time of this writing. Its 52 week high is $2.67, and its
52 week low is $0.59. The loan from Silicon Valley Bank gives the
bank warrants to purchase 293,531 shares of the company at $1.70 over
the next 10 years.

The 10-year loan from CIRM is low risk for the
company, which said its “obligation to repay the loan will be
contingent upon the success” of the research. If a product is
developed, it will take years before it could hit the market.

The award to StemCells, Inc., put
the stem cell agency in a touchy situation involving the company's decision last month to reject an additional $20 million award from
the agency.( It was the first time a recipient has rejected an award.) Neither the company nor the agency would give a reason for
the rejection of the loan for a spinal injury project . However, the
award also required a $20 million match, which undoubtedly tested the company's resources.

The spinal injury application was
scored at 79 by agency reviewers and was routinely approved by the
board. With its withdrawal by the company, the agency, which prides
itself on funding only the best science, was left supporting research
(StemCells, Inc.'s Alzheimer's project) judged significantly inferior
by reviewers with its score of 61.

In response to a question about that
situation, CIRM's McCormack said,

“Our goal is to always fund the best,
most promising science. This is not the first time that our board has
voted to fund a project that the Grants Review Group had not
recommended (this has happened in around 2% of cases) The board did
so for a number of reasons, not the least of which is that this was
the first disease team application that had a goal of moving a
promising stem cell therapy for Alzheimer's towards clinical
trials.”

The round in question, however, had another application dealing with Alzheimer's which was scored at 63,
two points higher than the one from StemCells, Inc. Reviewers also did not recommend funding that application.

The action last September by the
agency board came only after it publicly said the funds would not be
distributed until the StemCells, Inc., could show it could provide
the match, still another first for the agency.

The award triggered a column in
the Los Angeles Times by Pulitzer Prize winning writer Michael
Hiltzik, who said in October that the
process was “redolent of cronyism.” He said a “charmed
relationship” existed among StemCells, Inc., its “powerful
friends” and the stem cell agency.

StemCells, Inc., was founded by
Stanford researcher Irv Weissman, who was a major fundraiser for
Proposition 71, which created the stem cell agency in 2004. Klein
headed the ballot campaign, which spent more than $30 million to win
voter approval. Weissman sits on board of directors of StemCells,
Inc., and holds 124,608 shares in the firm, including 8,630 he reported this month receiving.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/34J6wy7wpLY/stemcells-inc-nails-down-controversial.html

♫ Posted in Stem Cell Therapy, Stem Cells | | Comments Off»

Modest Approval from Long-time Stem Cell Agency Critic

♫ Sunday, April 14th, 2013

Of all California's newspapers, The
Sacramento Bee, the only daily paper in the state capital, has long
been the most critical – editorially – of the Golden State's $3
billion stem cell research agency.

Today, however, the newspaper gave a
modest nod of approval to the agency's modest efforts to clean up its
built-in conflicts of interest, which have been cited as a major flaw
by the prestigious Institute of Medicine.

The headline on the Bee's editorial today said,

“Stem cell agency finally addresses
potential for conflicts”

The piece said that Jonathan Thomas,
chairman of the agency, “has taken important steps in
reducing the potential for conflicts within this agency.”

The editorial continued,

“He hasn't
gone as far as we would like, or that independent outside reviewers
have recommended....But he's achieved what's possible, at least for
now, and the board may empower him to go further.”

The Bee referred to action last month
in which the agency's governing board decided, among other things,
that 13 of the 15 board members linked to recipient institutions
could not vote on any grants, although they could participate in
discussion of applications. Twenty-nine persons sit on the board. In
a $700,000 report commissioned by the agency, the Institute of
Medicine recommended a fully independent board.

The Sacramento newspaper said,

“We
think Thomas and the oversight board should go further and adopt the
Institute of Medicine recommendations. But that is politically
unlikely. As is now obvious, it will be up to the Legislature to
fully remove representatives of funding-eligible institutions from
being involved in decisions about grants that could come back to
them.

“Thomas, to his credit, recognizes
that his compromise may not be the perfect solution. He wants to test
out the new policy for a year, and see how it works. There's a lot
riding on the outcome. CIRM is expected to run out of funds in 2017,
and while philanthropy and foundation money could extend that for a
few years, supporters of California stem cell research clearly want
to go back to the ballot to seek additional funding. To make that
case, CIRM supporters can't afford any more scandals about insider
dealing. The next year will reveal whether it is on the right track.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/NowG2d8N5CM/modest-approval-from-long-time-stem.html

♫ Posted in Stem Cell Therapy, Stem Cells | | Comments Off»

Stem Cell Therapy – Blue Horizon Stem Cells – Video

♫ Thursday, April 11th, 2013

Stem Cell Therapy - Blue Horizon Stem Cells

By: Michael McDermott

See more here:
Stem Cell Therapy - Blue Horizon Stem Cells - Video

♫ Posted in Stem Cell Therapy | | Comments Off»

Stem Cell Therapy for Pets – Teddy Before

♫ Monday, April 8th, 2013

Stem Cell Therapy for Pets - Teddy Before After
Amazing before and after footage of Teddy, an 11 year old dog who received stem cell therapy for his arthritis and received an unexpected benefit to his hear...

By: NewmanVets

See the original post:
Stem Cell Therapy for Pets - Teddy Before

♫ Posted in Stem Cell Therapy | | Comments Off»

Purtier Placenta – Live Stem Cell Therapy (English version) – Video

♫ Monday, April 8th, 2013

Purtier Placenta - Live Stem Cell Therapy (English version)

By: Zoey Purtier

Originally posted here:
Purtier Placenta - Live Stem Cell Therapy (English version) - Video

♫ Posted in Stem Cell Therapy | | Comments Off»

Stem Cell Therapy for Pets — Taylor Before

♫ Sunday, April 7th, 2013

Stem Cell Therapy for Pets -- Taylor Before After
Amazing before and after footage of Taylor, a 7 year old dog who received stem cell therapy for arthritis in her hips, knees and ankles. For more information...

By: NewmanVets

See original here:
Stem Cell Therapy for Pets -- Taylor Before

♫ Posted in Stem Cell Therapy | | Comments Off»

StemCells, Inc., Rejects $20 Million from California Stem Cell Agency

♫ Sunday, April 7th, 2013

When does a financially struggling
biotech company turn down a $20 million “forgivable loan?”

When it is StemCells, Inc., of Newark,
Ca., and the cash is being offered by the $3 billion California stem
cell agency. The research program has handed out nearly 600 awards, and it is the first time that a recipient has rejected funding.

That's the latest development in a stem
cell saga that began publicly last July and that involved unusual personal lobbying by the former chairman of the Golden State's stem cell research agency. The high point of the saga may have come in
September when the agency's governing board finished awarding
StemCells, Inc., $40 million in two different awards. But there was a
catch. StemCells Inc., had to match that figure with $40 million of
its own.

Late last month, StemCells, Inc., threw
in the towel on the $20 million awarded on its cervical spinal cord
injury application. In comments to analysts March 21, Rodney Young,
chief financial officer of the publicly traded company, said:

“The funding would have been in the
form of a forgivable loan, however, we have elected not to borrow
these funds from CIRM(the stem cell agency).”

According to the Seeking Alpha transcript of the conference call with analysts, Young said,

“You may also recall that last
September, CIRM approved a separate application under the same
disease team program for Alzheimer's disease, which was also for up
to $20 million in the form of a loan. We remain in confidential
negotiations with CIRM regarding the terms and conditions that would
attach to this loan.”

The company provided no explanation for
rejecting the cash, either in the conference call transcript or in
its press release.

During the conference call, StemCells,
Inc., reported continuing losses. For 2012, net losses totaled $28.5
million compared to $21.3 million in 2011. Revenue for 2012 was $1.4
million compared to $1.2 million in the previous year.

The awards last year to StemCells,
Inc., founded by Stanford's eminent researcher Irv Weissman, stirred
up a bit of a ruckus. The spinal injury award was handed out
routinely in July. Scientific reviewers gave it a score of 79 and
recommended funding. It was another matter on the Alzheimer's
application. It was scored at 61. Reviewers said it did not merit
funding. But the company publicly appealed to the full board, which sent the
application back for more examination. It was rejected again.
Nonetheless, in September, the 29-member board approved the award on
a 7-5 vote, bypassing a rival Alzheimer's application scored at 63.
It was the first time in the eight-year-history of the agency that
its board approved an application that was rejected twice by
reviewers.

Approval came only after strong
lobbying by Robert Klein, former chairman of the board. Klein was
also chairman of the ballot campaign that created the agency, and
Weissman, who holds stock in StemCells, Inc., and sits on its board,
was a major fundraiser for the campaign.

The Los Angeles Times' Pulitzer
Prize-winning columnist, Michael Hiltzik, wrote in October that
the process was “redolent of cronyism.” He said a
“charmed relationship” existed among StemCells, Inc., its
“powerful friends” and the stem cell agency.

As for the remaining $20 million award,
Martin McGlynn, CEO of StemCells, Inc., expects “quick” action on
finally securing the cash.

Here is an exchange that came during
the March conference call between McGlynn and analyst Kaey Nakae of
Ascendiant Capital Markets.

Nakae: “Okay. Just 2 more questions.
I guess the first one, as it relates to CIRM.
In deciding to decline the funding for spinal cord yet continuing to
pursue the funding for Alzheimer's, is there a difference in what
you're getting from them in terms of potential terms and conditions
that allow you to proceed on one and not the other, or is it the fact
that you're already in human with -- in spine, and still very
preclinical with Alzheimer's?”

McGlynn: :”I think you're very
definitely -- you're getting at some important criteria when one
considers how to fund programs whether you use debt or equity,
etcetera. So I wouldn't disagree with anything that you've outlined
or surmised. But I just would pray your indulgence until we're
finished, the negotiations with CIRM, which are coming to a close and
we expect those to resolve pretty quickly with regards to the
Alzheimer's program. And then quite frankly, we can be way more
forthcoming and way more disclosive with regards not only to our
decisions, but to our thinking.”

StemCells, Inc., was trading at about $1.65 at the time of this writing, down slightly from the previous
day. Its 52-week high is $2.67 and its 52-week low $0.59.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/zYvykN1XE6k/stemcells-inc-rejects-20-million-from.html

♫ Posted in Stem Cell Therapy | | Comments Off»

StemCells, Inc., Rejects $20 Million from California Stem Cell Agency

♫ Sunday, April 7th, 2013

When does a financially struggling
biotech company turn down a $20 million “forgivable loan?”

When it is StemCells, Inc., of Newark,
Ca., and the cash is being offered by the $3 billion California stem
cell agency. The research program has handed out nearly 600 awards, and it is the first time that a recipient has rejected funding.

That's the latest development in a stem
cell saga that began publicly last July and that involved unusual personal lobbying by the former chairman of the Golden State's stem cell research agency. The high point of the saga may have come in
September when the agency's governing board finished awarding
StemCells, Inc., $40 million in two different awards. But there was a
catch. StemCells Inc., had to match that figure with $40 million of
its own.

Late last month, StemCells, Inc., threw
in the towel on the $20 million awarded on its cervical spinal cord
injury application. In comments to analysts March 21, Rodney Young,
chief financial officer of the publicly traded company, said:

“The funding would have been in the
form of a forgivable loan, however, we have elected not to borrow
these funds from CIRM(the stem cell agency).”

According to the Seeking Alpha transcript of the conference call with analysts, Young said,

“You may also recall that last
September, CIRM approved a separate application under the same
disease team program for Alzheimer's disease, which was also for up
to $20 million in the form of a loan. We remain in confidential
negotiations with CIRM regarding the terms and conditions that would
attach to this loan.”

The company provided no explanation for
rejecting the cash, either in the conference call transcript or in
its press release.

During the conference call, StemCells,
Inc., reported continuing losses. For 2012, net losses totaled $28.5
million compared to $21.3 million in 2011. Revenue for 2012 was $1.4
million compared to $1.2 million in the previous year.

The awards last year to StemCells,
Inc., founded by Stanford's eminent researcher Irv Weissman, stirred
up a bit of a ruckus. The spinal injury award was handed out
routinely in July. Scientific reviewers gave it a score of 79 and
recommended funding. It was another matter on the Alzheimer's
application. It was scored at 61. Reviewers said it did not merit
funding. But the company publicly appealed to the full board, which sent the
application back for more examination. It was rejected again.
Nonetheless, in September, the 29-member board approved the award on
a 7-5 vote, bypassing a rival Alzheimer's application scored at 63.
It was the first time in the eight-year-history of the agency that
its board approved an application that was rejected twice by
reviewers.

Approval came only after strong
lobbying by Robert Klein, former chairman of the board. Klein was
also chairman of the ballot campaign that created the agency, and
Weissman, who holds stock in StemCells, Inc., and sits on its board,
was a major fundraiser for the campaign.

The Los Angeles Times' Pulitzer
Prize-winning columnist, Michael Hiltzik, wrote in October that
the process was “redolent of cronyism.” He said a
“charmed relationship” existed among StemCells, Inc., its
“powerful friends” and the stem cell agency.

As for the remaining $20 million award,
Martin McGlynn, CEO of StemCells, Inc., expects “quick” action on
finally securing the cash.

Here is an exchange that came during
the March conference call between McGlynn and analyst Kaey Nakae of
Ascendiant Capital Markets.

Nakae: “Okay. Just 2 more questions.
I guess the first one, as it relates to CIRM.
In deciding to decline the funding for spinal cord yet continuing to
pursue the funding for Alzheimer's, is there a difference in what
you're getting from them in terms of potential terms and conditions
that allow you to proceed on one and not the other, or is it the fact
that you're already in human with -- in spine, and still very
preclinical with Alzheimer's?”

McGlynn: :”I think you're very
definitely -- you're getting at some important criteria when one
considers how to fund programs whether you use debt or equity,
etcetera. So I wouldn't disagree with anything that you've outlined
or surmised. But I just would pray your indulgence until we're
finished, the negotiations with CIRM, which are coming to a close and
we expect those to resolve pretty quickly with regards to the
Alzheimer's program. And then quite frankly, we can be way more
forthcoming and way more disclosive with regards not only to our
decisions, but to our thinking.”

StemCells, Inc., was trading at about $1.65 at the time of this writing, down slightly from the previous
day. Its 52-week high is $2.67 and its 52-week low $0.59.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/zYvykN1XE6k/stemcells-inc-rejects-20-million-from.html

♫ Posted in Stem Cell Therapy, Stem Cells | | Comments Off»

Stem Cell Therapy Treatment Improvements in Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. – Video

♫ Wednesday, April 3rd, 2013

Stem Cell Therapy Treatment Improvements in Muscular Dystrophy by Dr Alok Sharma, Mumbai, India.
Stem Cell Therapy Treatment Improvements in Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1. Could stand with calipers and wal...

By: neurogenbsi

See the original post:
Stem Cell Therapy Treatment Improvements in Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. - Video

♫ Posted in Stem Cell Therapy | | Comments Off»

Stem Cell Therapy Treatment for Spinal Cord Injury by Dr Alok Sharma, Mumbai, India. – Video

♫ Wednesday, April 3rd, 2013

Stem Cell Therapy Treatment for Spinal Cord Injury by Dr Alok Sharma, Mumbai, India.
Stem Cell Therapy Treatment for Spinal Cord Injury by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1. Ankle clonus/jerk in both legs has reduced. P...

By: neurogenbsi

Original post:
Stem Cell Therapy Treatment for Spinal Cord Injury by Dr Alok Sharma, Mumbai, India. - Video

♫ Posted in Stem Cell Therapy | | Comments Off»

Stem Cell Therapy Treatment for Cerebral Palsy by Dr Alok Sharma, Mumbai, India. – Video

♫ Wednesday, April 3rd, 2013

Stem Cell Therapy Treatment for Cerebral Palsy by Dr Alok Sharma, Mumbai, India.
Stem Cell Therapy Treatment for Cerebral Palsy by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy PT assessment: 1) Speech has improved. Now he is abl...

By: neurogenbsi

Read the rest here:
Stem Cell Therapy Treatment for Cerebral Palsy by Dr Alok Sharma, Mumbai, India. - Video

♫ Posted in Stem Cell Therapy | | Comments Off»

More about Funding for Personalized Medicine Research

♫ Sunday, March 31st, 2013

A post entitled Funding for Personalized Medicine Research, dated January 31, 2012, provided information about the participation of the Cancer Stem Cell Consortium (CSCC) in the Large-Scale Applied Research Project Competition of Genome Canada, in collaboration with the first phase of the Personalized Medicine Signature Initiative of the Canadian Institutes of Health Research (CIHR).

On March 26, 2013, it was announced that 17 projects will be supported. A list of these project is available (PDF). One of the 17 projects is entitled "Innovative chemogenomic tools to improve outcome in acute myeloid leukemia". The Project leader is Guy Sauvageau of the Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal. The Project co-leader is Josée Hébert of the Centre de Recherche Hôpital Maisonneuve-Rosemont, Montréal. One of the aims of this project is to develop new models for tracking cancer stem cells that are left behind after a patient is treated.

Source:
http://cancerstemcellnews.blogspot.com/2013/03/more-about-funding-for-personalized.html

♫ Posted in Stem Cell Therapy | | Comments Off»

More about Funding for Personalized Medicine Research

♫ Sunday, March 31st, 2013

A post entitled Funding for Personalized Medicine Research, dated January 31, 2012, provided information about the participation of the Cancer Stem Cell Consortium (CSCC) in the Large-Scale Applied Research Project Competition of Genome Canada, in collaboration with the first phase of the Personalized Medicine Signature Initiative of the Canadian Institutes of Health Research (CIHR).

On March 26, 2013, it was announced that 17 projects will be supported. A list of these project is available (PDF). One of the 17 projects is entitled "Innovative chemogenomic tools to improve outcome in acute myeloid leukemia". The Project leader is Guy Sauvageau of the Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal. The Project co-leader is Josée Hébert of the Centre de Recherche Hôpital Maisonneuve-Rosemont, Montréal. One of the aims of this project is to develop new models for tracking cancer stem cells that are left behind after a patient is treated.

Source:
http://cancerstemcellnews.blogspot.com/2013/03/more-about-funding-for-personalized.html

♫ Posted in Stem Cell Therapy, Stem Cells | | Comments Off»

Stem Cell Therapy Treatment for Spinal Cord Injury by Dr Alok Sharma – Video

♫ Friday, March 29th, 2013

Stem Cell Therapy Treatment for Spinal Cord Injury by Dr Alok Sharma
Stem Cell Therapy Treatment for Spinal Cord Injury by Dr Alok Sharma After Stem Cell Therapy 1) Ankle dorsiflexion movements are possible now. 2) He is able ...

By: neurogenbsi

Continued here:
Stem Cell Therapy Treatment for Spinal Cord Injury by Dr Alok Sharma - Video

♫ Posted in Stem Cell Therapy | | Comments Off»

Stem Cell Therapy Treatment for Autism by Dr Alok Sharma – Video

♫ Friday, March 29th, 2013

Stem Cell Therapy Treatment for Autism by Dr Alok Sharma

By: neurogenbsi

See the original post here:
Stem Cell Therapy Treatment for Autism by Dr Alok Sharma - Video

♫ Posted in Stem Cell Therapy | | Comments Off»

Stem Cell Therapy Treatment for Autism by Dr Alok Sharma Mumbai India – Video

♫ Friday, March 29th, 2013

Stem Cell Therapy Treatment for Autism by Dr Alok Sharma Mumbai India

By: neurogenbsi

Original post:
Stem Cell Therapy Treatment for Autism by Dr Alok Sharma Mumbai India - Video

♫ Posted in Stem Cell Therapy | | Comments Off»

Stem Cell Therapy for Pets – Bandit Before

♫ Friday, March 29th, 2013

Stem Cell Therapy for Pets - Bandit Before After
Amazing before and after footage of Bandit, a 5 year old dog who received stem cell therapy for his arthritis and hip dysplasia. For more information about s...

By: NewmanVets

♫ Posted in Stem Cell Therapy | | Comments Off»

StemCell Therapy

Archive for the ‘Stem Cell Therapy’ Category

Vatican hosts conference on advancements in stem cell therapy – Video

StemCells, Inc., Nails Down Controversial, $19 Million Award from California Stem Cell Agency

Modest Approval from Long-time Stem Cell Agency Critic

StemCells, Inc., Nails Down Controversial, $19 Million Award from California Stem Cell Agency

Modest Approval from Long-time Stem Cell Agency Critic

Stem Cell Therapy – Blue Horizon Stem Cells – Video

Stem Cell Therapy for Pets – Teddy Before

Purtier Placenta – Live Stem Cell Therapy (English version) – Video

Stem Cell Therapy for Pets — Taylor Before

StemCells, Inc., Rejects $20 Million from California Stem Cell Agency

StemCells, Inc., Rejects $20 Million from California Stem Cell Agency

Stem Cell Therapy Treatment Improvements in Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. – Video

Stem Cell Therapy Treatment for Spinal Cord Injury by Dr Alok Sharma, Mumbai, India. – Video

Stem Cell Therapy Treatment for Cerebral Palsy by Dr Alok Sharma, Mumbai, India. – Video

More about Funding for Personalized Medicine Research

More about Funding for Personalized Medicine Research

Stem Cell Therapy Treatment for Spinal Cord Injury by Dr Alok Sharma – Video

Stem Cell Therapy Treatment for Autism by Dr Alok Sharma – Video

Stem Cell Therapy Treatment for Autism by Dr Alok Sharma Mumbai India – Video

Stem Cell Therapy for Pets – Bandit Before

Categories

Archives

Recommended Sites

Recent Posts